Our group aims to gain a better understanding of the clinical characteristics and mechanisms of progression and therapeutic resistance of hematological tumors with a focus on multiple myeloma and aggressive T and B lymphomas to propose new therapeutic strategies.
The lab is interested in improving the understanding of the molecular mechanisms leading to the progression and therapeutic resistance of multiple myeloma, including extramedullary disease, Hodgkin lymphoma and aggressive non-Hodgkin B and T lymphomas.
To develop these lines of research, we use patient samples and advanced preclinical models for therapeutic, mechanistic and functional studies. We have developed the technology to generate murine models derived from patients by orthotopic implantation (orthotopic PDX) and 2D/3D cultures that we can humanize using components of the human immune system (from the same patient from whom the model has been derived, when possible). Additionally, we are involved in a project that is developing humanized nanomedicines as a new therapeutic strategy for acute myeloid leukemia.
Our group is integrated by professionals from the Clinical Hematology Service of ICO/Hospitalet, the ProCURE/ICO Program and the Pathology Service of the Hospital of Bellvitge. Within the Hematology Service of the ICO Hospitalet, one of our main objectives is to promote translational research training for the professionals of the Service, generating opportunities for the completion of doctoral theses and stimulating new scientific leadership as well as to attract talent with a mixed clinical/researcher profile for the Service.
Group members
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Clinical collaborator
Clinical collaborator
Clinical collaborator
Clinical collaborator
Predoctoral researcher
Posdoctoral researcher
Publications
Farm Hosp. 2026 Oct 15:S1130-6343(26)00234-5. doi: 10.1016/j.farma.2026.10.001. Online ahead of print. NO ABSTRACT PMID:42881011 | DOI:10.1016/j.farma.2026.10.001
Bone Marrow Transplant. 2026 Oct 12. doi: 10.1038/s41409-026-03046-1. Online ahead of print. NO ABSTRACT PMID:42864395 | DOI:10.1038/s41409-026-03046-1
PLoS One. 2026 Oct 8;21(10):e0360080. doi: 10.1371/journal.pone.0360080. eCollection 2026. ABSTRACT BACKGROUND: In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, none have achieved the accuracy to be included […]
Bone Marrow Transplant. 2026 Oct 6. doi: 10.1038/s41409-026-03043-4. Online ahead of print. ABSTRACT BEAM (carmustine, etoposide, cytarabine, and melphalan) remains the most used chemotherapy for autologous hematopoietic stem cell transplantation (HSCT) in chemosensitive relapsed Hodgkin’s lymphoma (HL). Nevertheless, alternatives have been developed to overcome drugs availability, costs, or potential toxicities. These include BeEAM (substitute carmustine […]
Bone Marrow Transplant. 2026 Sep 24. doi: 10.1038/s41409-026-03044-3. Online ahead of print. ABSTRACT Chimeric antigen receptor T-cell therapy transformed the treatment of hematologic malignancies and is rapidly expanding into solid tumors and autoimmune diseases. However, its full clinical potential remains constrained by centralized manufacturing, production costs, logistical complexity, prolonged vein-to-vein times, limited global accessibility, and […]
Research Projects
PI21/00684. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. ISCIII/AES. Budget: 135.520,00 euros, 2022 – 2024. PI: Anna Sureda, Co-PI: Lourdes Farre.
201941-30. Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. Marató TV3. Budget: 99.960,81 euros, 2020 – 2024. Projecte coordinat. Sub-projecte PI: Dra. Lourdes Farre
Collaborations
Isolda Casanova. Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Toni Villaverde. Institut de Biotecnologia i de Biomedicina. Universitat Autònoma de Barcelona, Bellaterra, Spain
Sonia Guil. Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Casanovas’ Lab